Trial intelligence / Profile preview

Subcutaneous Tocilizumab in Rheumatoid Arthritis

NCT01995201Phase 3Completed

Sponsor
Roche
Start
Sep 2013
Primary completion
Jul 2015
Modality
Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
Countries
3
01

Overview

A Phase 3 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Sep 2013; status: completed.

02

Drugs

tocilizumab
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on NCT01995201.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01995201.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call